Index RUT
P/E -
EPS (ttm) -3.18
Insider Own 5.04%
Shs Outstand 139.51M
Perf Week 23.54%
Market Cap 2.40B
Forward P/E -
EPS next Y -0.09
Insider Trans -1.07%
Shs Float 133.33M
Perf Month 30.51%
Income -398.71M
PEG -
EPS next Q 0.98
Inst Own 48.81%
Short Float 23.55%
Perf Quarter 333.16%
Sales 996.61M
P/S 2.41
EPS this Y 107.83%
Inst Trans 3.20%
Short Ratio 1.84
Perf Half Y 317.32%
Book/sh -6.18
P/B -
EPS next Y -121.73%
ROA -27.53%
Short Interest 31.40M
Perf Year 108.15%
Cash/sh 3.50
P/C 4.89
EPS next 5Y 37.90%
ROE -
52W Range 3.53 - 23.86
Perf YTD 256.46%
Dividend Est. -
P/FCF -
EPS past 5Y 11.55%
ROI -
52W High -28.29%
Beta 1.94
Dividend TTM -
Quick Ratio 0.88
Sales past 5Y 513.29%
Gross Margin 64.69%
52W Low 384.37%
ATR (14) 1.36
Dividend Ex-Date Dec 13, 2007
Current Ratio 0.90
EPS Y/Y TTM 78.36%
Oper. Margin -37.92%
RSI (14) 62.33
Volatility 9.49% 8.36%
Employees 1543
Debt/Eq -
Sales Y/Y TTM -26.66%
Profit Margin -40.01%
Recom 2.00
Target Price 21.40
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 69.08%
Payout -
Rel Volume 0.42
Prev Close 16.67
Sales Surprise -7.22%
EPS Surprise 1.32%
Sales Q/Q 15.94%
Earnings May 10 BMO
Avg Volume 17.05M
Price 17.11
SMA20 23.46%
SMA50 15.98%
SMA200 125.55%
Trades
Volume 7,125,461
Change 2.64%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-24 Upgrade
JP Morgan
Underweight → Neutral
May-10-24 Upgrade
BofA Securities
Underperform → Neutral
$4 → $12
Aug-09-23 Upgrade
B. Riley Securities
Neutral → Buy
$15
Apr-20-23 Downgrade
TD Cowen
Outperform → Market Perform
$55 → $10
Mar-01-23 Downgrade
B. Riley Securities
Buy → Neutral
$29 → $10
Jan-09-23 Reiterated
B. Riley Securities
Buy
$74 → $37
Dec-30-22 Reiterated
H.C. Wainwright
Buy
$207 → $110
Dec-02-22 Initiated
Jefferies
Hold
Sep-22-22 Downgrade
JP Morgan
Neutral → Underweight
$132 → $27
May-20-22 Initiated
BofA Securities
Underperform
$35
Feb-23-22 Reiterated
B. Riley Securities
Buy
$315 → $265
Feb-22-22 Resumed
Jefferies
Buy
$198
Jan-21-22 Initiated
Cowen
Outperform
$150
May-12-21 Downgrade
JP Morgan
Overweight → Neutral
$285 → $161
Dec-14-20 Initiated
Jefferies
Buy
$200
Aug-06-20 Reiterated
H.C. Wainwright
Buy
$132 → $290
Aug-05-20 Upgrade
JP Morgan
Neutral → Overweight
$275
Aug-05-20 Downgrade
Ladenburg Thalmann
Neutral → Sell
$105
Jul-16-20 Reiterated
H.C. Wainwright
Buy
$101 → $132
Jul-08-20 Downgrade
Ladenburg Thalmann
Buy → Neutral
$50 → $105
Show Previous Ratings
Jul-25-24 01:28PM
(Investor's Business Daily) +8.25%
Jul-23-24 09:41AM
Jul-16-24 09:00AM
Jul-15-24 09:30AM
Jul-08-24 05:45PM
06:55AM
Loading…
Jul-03-24 06:55AM
Jul-02-24 08:30AM
Jul-01-24 11:00PM
07:38AM
Jun-29-24 08:55AM
08:35AM
Jun-28-24 05:45PM
06:30AM
Jun-27-24 02:21PM
Jun-25-24 07:00PM
04:37PM
Loading…
04:37PM
11:42AM
06:33AM
(Pharmaceutical Technology)
Jun-24-24 09:18AM
09:00AM
Jun-22-24 03:42AM
Jun-20-24 05:45PM
Jun-18-24 10:29AM
05:52AM
(Pharmaceutical Technology)
Jun-17-24 12:02PM
04:32AM
(Pharmaceutical Technology)
Jun-14-24 02:05PM
04:55AM
Jun-13-24 11:02AM
Jun-11-24 06:00AM
05:10AM
Loading…
05:10AM
Jun-10-24 09:00AM
Jun-07-24 07:30AM
Jun-06-24 04:37PM
04:15PM
(Investor's Business Daily)
11:38AM
10:48AM
09:58AM
09:28AM
Jun-05-24 04:51PM
Jun-04-24 06:00AM
Jun-03-24 05:43PM
(Yahoo Finance Video) +21.22%
03:41PM
01:23PM
Jun-01-24 06:01AM
May-31-24 06:57AM
May-30-24 09:25AM
May-28-24 09:00AM
May-24-24 05:55PM
08:15AM
May-23-24 12:45PM
(The Wall Street Journal)
06:45AM
May-22-24 10:48AM
09:45AM
05:50AM
May-21-24 09:01AM
06:27AM
May-20-24 03:29PM
02:31PM
01:53PM
Hedge Fund and Insider Trading News: Ray Dalio, Michael Burry, David Tepper, Elliott Management, Greenlight Capital, Ghisallo Capital Management, Millennium Management, Nextnav Inc (NN), Williams-Sonoma, Inc. (WSM), and More
(Insider Monkey)
01:37PM
07:40AM
07:39AM
06:35AM
May-19-24 08:49AM
May-18-24 07:35AM
May-17-24 06:45AM
05:40AM
May-16-24 09:15AM
06:34AM
May-15-24 02:31PM
08:00AM
06:48AM
06:32AM
05:35AM
May-14-24 11:01AM
(Investor's Business Daily)
10:24AM
06:47AM
05:11AM
May-13-24 04:02PM
12:51PM
10:24AM
03:03AM
May-10-24 06:56PM
05:56PM
04:26PM
04:16PM
04:11PM
04:08PM
02:54PM
01:58PM
(The Wall Street Journal)
01:46PM
01:44PM
01:27PM
01:24PM
01:24PM
01:08PM
01:07PM
01:02PM
12:49PM
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
YOUNG JAMES F Director Jun 21 '24 Sale 14.09 7,500 105,675 61,760 Jun 25 04:12 PM YOUNG JAMES F Director Jun 18 '24 Sale 13.72 7,500 102,881 69,260 Jun 21 04:21 PM Dubovsky Filip President, R&D Jun 17 '24 Option Exercise 6.18 13,904 85,911 80,517 Jun 20 05:08 PM Dubovsky Filip President, R&D Jun 17 '24 Sale 14.47 13,904 201,164 66,613 Jun 20 05:08 PM MCGLYNN MARGARET G Director Jun 12 '24 Option Exercise 0.00 6,670 0 10,470 Jun 14 04:14 PM Alton Gregg H Director Jun 12 '24 Option Exercise 0.00 6,670 0 10,470 Jun 14 04:11 PM DOUGLAS RICHARD Director Jun 12 '24 Option Exercise 0.00 6,670 0 43,920 Jun 14 04:10 PM MOTT DAVID M Director Jun 12 '24 Option Exercise 0.00 6,670 0 50,470 Jun 14 04:06 PM King Rachel K. Director Jun 12 '24 Option Exercise 0.00 6,670 0 18,920 Jun 14 04:07 PM Rodgers Richard J Director Jun 12 '24 Option Exercise 0.00 6,670 0 10,470 Jun 14 04:05 PM YOUNG JAMES F Director Jun 12 '24 Option Exercise 0.00 6,670 0 76,760 Jun 14 04:01 PM Dubovsky Filip President, R&D May 14 '24 Option Exercise 6.97 19,652 136,974 86,265 May 15 09:15 PM Dubovsky Filip President, R&D May 14 '24 Sale 13.90 47,312 657,637 38,953 May 15 09:15 PM O'Hara Elaine EVP, Chief Strategy Officer Mar 01 '24 Option Exercise 5.39 19,600 105,644 19,600 Mar 05 07:30 PM Dubovsky Filip President, R&D Dec 14 '23 Option Exercise 5.69 2,833 16,120 55,150 Dec 18 05:00 PM Dubovsky Filip President, R&D Nov 05 '23 Option Exercise 7.06 1,400 9,884 52,994 Nov 07 05:30 PM Dubovsky Filip President, R&D Sep 16 '23 Option Exercise 7.71 12,644 97,485 57,702 Sep 19 05:16 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite